Hims & Hers Health, Inc.

Revenue is forecast to grow 14% per annum over the next three years, and analysts at Canaccord Genuity and Barclays have set price targets of $40 and $39 respectively, reflecting confidence in Hims & Hers' ability to capitalize on the surging demand for weight-loss drug services, including its GLP-1 offerings.

BTIG downgraded the stock to Neutral, citing increased legal and regulatory risk around the GLP-1 franchise. Citi kept a Sell rating, noting that key questions surrounding the GLP-1 strategy were left unanswered, while the FDA's late-July peptide review adds further uncertainty to the company's core growth thesis.

Earnings per share surpassed analyst estimates by 7.4%, and the company reported $2.35B in revenue in 2025 with a net income of $128.37M, suggesting an underlying earnings capability that some analysts believe will reassert itself as the company scales its newer product lines.

The 2026 outlook projects a net loss, and Q1 results showed gross margin compression alongside an 8% decline in U.S. revenue. Morgan Stanley slashed its price target nearly 50% to $21, while Bank of America maintained an Underperform rating, both highlighting weak guidance and fiscal 2026 back-half weighting as key concerns.

B of A Securities raised its price target to $37, and Needham set a target of $35, with both reflecting a view that Hims & Hers' expanding portfolio of oral weight-loss products and its telehealth platform position it to sustain subscriber growth and improve retention metrics over the coming year.

A B of A Securities analyst flagged emerging signs that retention for new oral Wegovy members may be weaker than investors expected, while Truist reiterated a Hold rating with a $23 price target, emphasizing that uncertainty around the peptide opportunity ahead of the FDA advisory meeting is a material overhang.